Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
Portfolio Pulse from Avi Kapoor
On CNBC's 'Halftime Report Final Trades,' analysts provided updates on Uber Technologies, Sprott Uranium Miners ETF, Abbott Laboratories, and Vertex Pharmaceuticals. Uber's stock hit an all-time high, with a raised price target from Goldman Sachs. Uranium is expected to have another strong year, supporting URNM. Abbott Laboratories received a higher price target from RBC Capital. Vertex Pharmaceuticals also reached an all-time high and announced the approval of a gene-edited therapy in Saudi Arabia. Stock movements included gains for Uber and Vertex, while URNM and Abbott Laboratories saw declines.
January 12, 2024 | 1:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abbott Laboratories' stock fell slightly, but the company received a higher price target from RBC Capital, indicating potential for future gains.
The raised price target suggests analyst confidence in Abbott's growth potential, which could lead to a positive short-term impact on the stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 80
POSITIVE IMPACT
Uber Technologies hit an all-time high with a raised price target from Goldman Sachs, indicating strong performance and continued analyst confidence.
The all-time high and increased price target from a reputable analyst suggest a positive short-term impact on Uber's stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Sprott Uranium Miners ETF is expected to benefit from another strong year in the uranium market, despite a recent drop in price.
Positive market outlook for uranium suggests potential recovery and gains for URNM, despite the short-term price fall.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 70
POSITIVE IMPACT
Vertex Pharmaceuticals reached an all-time high and announced the approval of a gene-edited therapy, signaling strong momentum and innovation.
The all-time high and therapy approval in Saudi Arabia are significant positive developments that are likely to have a favorable short-term impact on Vertex's stock.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 90